$Exel Deeply discounted 7.4B Mcap, 
Revenue 900M, 
1.4B in cash.
 Phase 3 Radioiodine-refractory Differentiate d Thyroid Cancer  Primary Completion July 2020:
 $jnj $sgen $amgn $gild $mrk $abbv $pfe $bmrn $bmy $rhhby $sny $azn $lly $jazz $vrtx $regn $GBT $BLUE